Lee SW, Kwon JH, Lee HL, et al. – Researchers performed a large-scale, propensity score analysis to compare tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) with respect to the risk of hepatocellular carcinoma (HCC) and mortality. The study sample consisted of 3,022 consecutive patients with CHB who were treated with TDF or ETV between February 2007 and January 2018 at the liver units of the Catholic University of Korea. Study end points were defined as HCC and all-cause mortality or liver transplantation (LT) within 5 years after the initiation of antiviral therapy, and the investigators used propensity score matching (PSM) and inverse probability of treatment weighting methods for their analyses. Overall, they did not identify any difference in the intermediate-term risk of HCC and mortality or LT between the two agents.